Bristol-Myers Squibb Company (BMY)

NYSE
Currency in USD
47.23
-1.43(-2.94%)
Closed·
After Hours
47.17-0.06(-0.14%)
·
BMY Scorecard
Full Analysis
High shareholder yield
High dividend Yield
Fair Value
Day's Range
47.1648.56
52 wk Range
39.3563.33
Key Statistics
Edit
Prev. Close
48.66
Open
48.4
Day's Range
47.16-48.56
52 wk Range
39.35-63.33
Volume
12.45M
Average Volume (3m)
14.53M
1-Year Change
15.28%
Book Value / Share
8.55
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BMY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
57.10
Upside
+20.89%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 3 consecutive years
Show more

Bristol-Myers Squibb Company Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Employees
34100

Bristol-Myers Squibb Company SWOT Analysis


Pipeline Potential
Explore BMY's promising drug candidates, including Cobenfy for schizophrenia and Arlo-cel for multiple myeloma, poised to address unmet medical needs
Market Challenges
Delve into BMY's strategies to navigate patent expirations, generic competition, and intense rivalry in key therapeutic areas like oncology
Financial Resilience
BMY's strong fundamentals, with $47.64B in revenue and 74.69% gross margin, support its 5.29% dividend yield and 55-year dividend streak
Analyst Outlook
Price targets range from $43 to $62, reflecting varied perspectives on BMY's growth potential amid product launches and market uncertainties
Read full SWOT analysis

Bristol-Myers Squibb Company Earnings Call Summary for Q1/2025

  • Q1 2025 EPS of $1.80 surpassed $1.52 forecast; revenue reached $11.2B, exceeding $10.68B estimate
  • Growth portfolio sales up 18%; company raised full-year revenue guidance to $45.8-$46.8B
  • Stock dipped 0.72% pre-market despite earnings beat; analysts' price targets range from $36 to $70
  • CEO emphasized strong growth portfolio performance, advancing pipeline, and focus on business development
  • Company projects non-GAAP EPS of $6.70-$7.00 for 2025; aims for $2B annual cost savings by 2027
Last Updated: 25/04/2025, 12:08 am
Read Full Transcript

Compare BMY to Peers and Sector

Metrics to compare
BMY
Peers
Sector
Relationship
P/E Ratio
17.7x16.2x−0.4x
PEG Ratio
0.10−0.100.00
Price/Book
5.5x1.5x2.6x
Price / LTM Sales
2.0x2.9x3.0x
Upside (Analyst Target)
15.3%250.9%52.3%
Fair Value Upside
Unlock24.5%9.4%Unlock

Analyst Ratings

8 Buy
18 Hold
1 Sell
Ratings:
27 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 57.10
(+20.89% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.67%
Dividend Yield
5.10%
Industry Median 1.73%
Annualised payout
2.48
Paid quarterly
5-Years Growth
+7.24%
Growth Streak

Earnings

Latest Release
Apr 24, 2025
EPS / Forecast
1.80 / 1.52
Revenue / Forecast
11.20B / 10.68B
EPS Revisions
Last 90 days

BMY Income Statement

People Also Watch

290.05
AMGN
-1.86%
67.09
CVS
-0.92%
52.94
ON
-1.74%
119.92
DHI
-3.02%

FAQ

What Is the Bristol-Myers Squibb (BMY) Stock Price Today?

The Bristol-Myers Squibb stock price today is 47.23

What Stock Exchange Does Bristol-Myers Squibb Trade On?

Bristol-Myers Squibb is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Bristol-Myers Squibb?

The stock symbol for Bristol-Myers Squibb is "BMY."

Does Bristol-Myers Squibb Pay Dividends? What’s The Current Dividend Yield?

The Bristol-Myers Squibb dividend yield is 5.25%.

What Is the Bristol-Myers Squibb Market Cap?

As of today, Bristol-Myers Squibb market cap is 96.08B.

What Is Bristol-Myers Squibb's Earnings Per Share (TTM)?

The Bristol-Myers Squibb EPS (TTM) is 2.67.

When Is the Next Bristol-Myers Squibb Earnings Date?

Bristol-Myers Squibb will release its next earnings report on 30 July 2025.

From a Technical Analysis Perspective, Is BMY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Bristol-Myers Squibb Stock Split?

Bristol-Myers Squibb has split 5 times.

How Many Employees Does Bristol-Myers Squibb Have?

Bristol-Myers Squibb has 34100 employees.

What is the current trading status of Bristol-Myers Squibb (BMY)?

As of 17 June 2025, Bristol-Myers Squibb (BMY) is trading at a price of 47.23, with a previous close of 48.66. The stock has fluctuated within a day range of 47.16 to 48.56, while its 52-week range spans from 39.35 to 63.33.

What Is Bristol-Myers Squibb (BMY) Price Target According to Analysts?

The average 12-month price target for Bristol-Myers Squibb is USD57.09591, with a high estimate of USD68 and a low estimate of USD36. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +20.89% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.